Serum obtained from the immunized subject at visit 20 inhibited the binding of 100 and 50 ng RBD to ACE2 by more than 98% whereas median inhibitions obtained with sera from subjects vaccinated with licensed genetic vaccines (100 ng RBD: −8.6% to 98.3% inhibition, median inhibition: 16.0%; 50 ng RBD: −14.4% to 99.4% inhibition, median inhibition: 52.8%) and sera from COVID‐19 convalescent subjects were much lower. This evidence concerns the gene ACE2 and COVID-19.